Milestone Pharmaceuticals (MIST) News Today $1.48 +0.10 (+7.25%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.47 -0.01 (-0.41%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Milestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJJuly 11, 2025 | wsj.comMilestone says heart disorder therapy under FDA review againJuly 11, 2025 | msn.comMilestone Pharmaceuticals stock plunges on public offering announcementJuly 11, 2025 | au.investing.comMilestone Pharmaceuticals Shares Drop Sharply After Public Offering AnnouncementJuly 11, 2025 | msn.comWhy Is Milestone Pharmaceuticals Stock Plunging On Friday?July 11, 2025 | benzinga.comCrude Oil Rises Sharply; Milestone Pharmaceuticals Shares PlungeJuly 11, 2025 | benzinga.comMilestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common WarrantsJuly 11, 2025 | globenewswire.comMilestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal SprayJuly 11, 2025 | finance.yahoo.comMilestone Pharmaceuticals proposes capital raise via securities offeringJuly 11, 2025 | msn.comMilestone Pharmaceuticals Announces Proposed Public OfferingJuly 11, 2025 | globenewswire.comMilestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal SprayJuly 11, 2025 | globenewswire.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from AnalystsJuly 11, 2025 | americanbankingnews.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Hold" from AnalystsJuly 11, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (MIST) - Yahoo FinanceJuly 9, 2025 | ca.finance.yahoo.comMilestone Pharmaceuticals (NASDAQ:MIST) Shares Up 11.9% - Here's What HappenedJuly 8, 2025 | marketbeat.comWatch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For CardamystJuly 7, 2025 | seekingalpha.comAnalysts Conflicted on These Healthcare Names: Milestone Pharmaceuticals (MIST), Exact Sciences (EXAS) and Ascendis Pharma (ASND)July 2, 2025 | theglobeandmail.comMilestone Pharmaceuticals Inc (MIST) - Investing.comJune 29, 2025 | investing.comMilestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A MeetingJune 16, 2025 | finance.yahoo.comMilestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A MeetingJune 16, 2025 | globenewswire.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from BrokeragesJune 16, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Milestone Pharmaceuticals (NASDAQ:MIST)June 5, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Large Decrease in Short InterestJune 4, 2025 | marketbeat.comToronto Dominion Bank Buys New Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)June 1, 2025 | marketbeat.comMilestone Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comToronto Dominion Bank Makes New Investment in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 26, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Recommendation of "Hold" from AnalystsMay 24, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comRTW Investments LP Sells 750,000 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 18, 2025 | marketbeat.comMilestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 15, 2025 | finanznachrichten.deMilestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateMay 14, 2025 | globenewswire.comLion Point Capital LP Trims Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 14, 2025 | marketbeat.comMilestone Pharmaceuticals (MIST) Expected to Announce Earnings on MondayMay 7, 2025 | marketbeat.comBoxer Capital Management LLC Purchases Shares of 309,007 Milestone Pharmaceuticals Inc. (NASDAQ:MIST)May 4, 2025 | marketbeat.comNantahala Capital Management LLC Has $3.41 Million Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)April 30, 2025 | marketbeat.comMilestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVTApril 9, 2025 | seekingalpha.comMilestone Pharmaceuticals price target lowered to $10 from $25 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comTD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertaintyApril 2, 2025 | finance.yahoo.comMilestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD CowenApril 2, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Shares Hit New Low After FDA Rejects EtripamilMarch 29, 2025 | marketwatch.comMilestone Pharmaceuticals (NASDAQ:MIST) Given "Buy" Rating at HC WainwrightMarch 29, 2025 | marketbeat.comMilestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | finanznachrichten.deMilestone stock tumbles after FDA letter on etripamilMarch 28, 2025 | ca.investing.comMilestone Pharmaceuticals announces FDA issued CRL for etripamilMarch 28, 2025 | markets.businessinsider.comMilestone CRL affirms integrity of clinical data, says H.C. WainwrightMarch 28, 2025 | msn.comUS FDA declines to approve Milestone's heart rhythm nasal spray; shares halveMarch 28, 2025 | msn.comMilestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveMarch 28, 2025 | msn.comUS FDA declines to approve Milestone Pharma's heart rhythm nasal sprayMarch 28, 2025 | reuters.comFDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | globenewswire.comMilestone Pharmaceuticals to present clinical data on etripamilMarch 21, 2025 | markets.businessinsider.com Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address MIST Media Mentions By Week MIST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIST News Sentiment▼0.280.97▲Average Medical News Sentiment MIST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIST Articles This Week▼152▲MIST Articles Average Week Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SGMT News DBVT News ANNX News AVTE News ALLO News TVRD News ZYBT News CRDF News MREO News KOD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIST) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.